MatrixThis page contains information on Matrix for veterinary use.
The information provided typically includes the following:
- Matrix Indications
- Warnings and cautions for Matrix
- Direction and dosage information for Matrix
MatrixThis treatment applies to the following species:
FOR USE IN ANIMALS ONLY
Altrenogest solution 0.22% (2.2 mg/mL)
Use: For synchronization of estrus in sexually mature gilts that have had at least one estrous cycle. Treatment with altrenogest solution 0.22% results in estrus (standing heat) 4 to 9 days after completion of the 14-day treatment period.
Federal law prohibits extra-label use of this drug to enhance food and/or fiber production in animals.
Do Not Use: In gilts having a previous or current history of uterine inflammation (i.e., acute, subacute or chronic endometritis).
Keep this and all medication out of the reach of children.
Avoid skin contact. Wear vinyl, neoprene or nitrile protective gloves when handling this product. DO NOT USE LATEX GLOVES. Pregnant women or women who suspect they are pregnant should not handle MATRIX® (altrenogest) Solution 0.22%. Women of childbearing age should exercise extreme caution when handling this product. Accidental absorption could lead to a disruption of the menstrual cycle or prolongation of pregnancy. Wash off accidental spillage on the skin immediately with soap and water.
People who should not handle this product:
1. Women who are or suspect they are pregnant.
2. Anyone with thrombophlebitis or thromboembolic disorders or with a history of these events.
3. Anyone with cerebral-vascular or coronary-artery disease.
4. Women with known or suspected carcinoma of the breast.
5. People with known or suspected estrogen-dependent neoplasia.
6. Women with undiagnosed vaginal bleeding.
7. People with benign or malignant tumors which developed during the use of oral contraceptives or other estrogen containing products.
8. Anyone with liver dysfunction or disease.
Accidental exposure: Altrenogest is readily absorbed from contact with the skin. In addition, this oil based product can penetrate porous gloves. Altrenogest should not penetrate intact vinyl, neoprene or nitrile protective gloves; however, if there is leakage (i.e., pinhole, spillage, etc.) the contaminated area covered by such occlusive materials may have increased absorption. DO NOT USE LATEX GLOVES
The following measures are recommended in case of accidental exposure.
Skin Exposure: Wash immediately with soap and water.
Eye Exposure: Immediately flush with plenty of water for 15 minutes. Get medical attention.
If Swallowed: Do not induce vomiting. MATRIX® (altrenogest) Solution 0.22% contains an oil. Call a physician. Vomiting should be supervised by a physician because of possible pulmonary damage via aspiration of the oil base. If possible, bring the container and labeling to the physician.
Effects of Overexposure: There has been no human use of this specific product. The information contained in this section is extrapolated from data available on other products of the same pharmacological class that have been used in humans. Effects anticipated are due to the progestational activity of altrenogest. Acute effects after a single exposure are possible; however, continued daily exposure has the potential for more untoward effects such as disruption of the menstrual cycle, uterine or abdominal cramping, increased or decreased uterine bleeding, prolongation of pregnancy and headaches. The oil base may also cause complications if swallowed. In addition, the list of people who should not handle this product is based upon the known effects of progestins used in humans on a chronic basis.
Human Food Safety: Gilts must not be slaughtered for human consumption for 21 days after the last treatment.
Environmental Safety: Place empty drug containers, waste from rinsing the dosing gun, protective gloves or other articles that come in contact with this product in a leak-resistant container for disposal in accordance with applicable Federal, state and local regulations.
Adverse Reactions and Potential Safety Hazards: Underfeeding of MATRIX® may lead to the occurrence of cystic follicles.
When Using This Product: A small percentage (less than 5%) of treated gilts may exhibit estrus (standing heat) during the 14-day treatment period. Gilts nearing estrus at the start of the 14-day treatment period may express estrus early in that period.
Dosage and Directions: While wearing protective gloves, remove shipping cap and seal; replace with enclosed plastic dispensing cap. Connect the Matrix® Dosing Device to the solution bottle according to the dosing device instructions provided as an attachment to the Matrix® Dosing Device package.
Administer 6.8 mL (15 mg altrenogest) per gilt once daily for 14 consecutive days. Treat gilts on an individual animal basis by top-dressing MATRIX® on a portion of each gilt’s daily feed allowance. To produce the desired synchronization of estrus in a group of gilts, treat all of the gilts daily for the same 14-day period.
StorageStore Matrix® solution bottle and dosing device when loaded with solution for continued use at or below room temperature, 77°F (25°C). Close tightly.
● To report adverse reaction call Merck at 1-800-211-3573
● To obtain product information, including material safety data sheet (MSDS), call 1-800-441-8272.
● For additional information about adverse drug experience for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/Animal/Veterinary/SafetyHealth
NADA #141-222, Approved by FDA
Restricted Drug (California) - use only as directed.
Not for Human Use
Manufactured for: Intervet Inc (d/b/a Merck Animal Health), Madison, NJ 07940 a subsidiary of Merck & Co.
2 GIRALDA FARMS, MADISON, NJ, 07940
|Technical Service (Companion Animal):||800-224-5318|
|Technical Service (Livestock):||800-211-3573|
|Every effort has been made to ensure the accuracy of the Matrix information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-05-31